EFESO: Study on Juvenile Onset Eosinophilic Fasciitis
International Multicentre Cohort Study on Clinical Manifestations and Response to Therapy in Juvenile Onset Eosinophilic Fasciitis
Meyer Children's Hospital IRCCS
20 participants
May 15, 2025
OBSERVATIONAL
Conditions
Summary
Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.
Eligibility
Inclusion Criteria5
- Inclusion criterai:
- All patients diagnosed from 2000 to 31/12/2026
- minimum follow-up 6 months
- Age <18 years at diagnosis;
- All patients whose informed consent is collected in accordance with current local legislation will also be considered enrollable.
Exclusion Criteria3
- Age ≥18 years at diagnosis;
- Unwilling to participate into the study;
- A follow-up period < 6 months.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(15)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07348263